ValiRx ValiRx ValiBio ValiTherma ValiMedix
ValiBIO is an oncology diagnostics company founded in July 2007 and jointly supported by ValiRx plc (www.valirx.com), an AIM listed biotechnology company based in London, UK and BIO.be, a Belgian company of the Institut de Pathologie et de Genetique (IPG) which is the largest pathology analysis centre in Belgium. The company is based in laboratories at IPG.
Our Products
Live Quote
 
 
Our Strategy & Mission Statement Our Technologies Our Products Media & Press Releases Management Team  

HPV diagnostic products

Chronic infection by high risk Human Papilloma Virus (HPV) subtypes is associated with cervical cancer in women and screening for HPV infection helps prevent cervical cancer.

ValiBIO expects to launch a high-risk HPV infection test product in the next 12 months.

The company is developing a low cost, high throughput, rapid HPV test for the detection of infection by any of the known 15 high risk HPV subtypes.

NucleosomicsTM diagnostic products

Nucleosomics is a platform for non-invasive (blood) tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy.

ELISA tests for global histone modifications expressed in cell free nucleosomes in blood that are characteristic of cancers are currently under development. The company expects to launch early Nucleosomics products for research use in 2009. Diagnostic products regulated by EMEA and the FDA will follow. Early disease focus is in lung, pancreatic and colon cancer.

HyperGenomicsTM diagnostic products

HyperGenomicsTM is a platform for differential diagnostic and prognostic tests in cancer as well as testing for personalised medicine.

ValiBIO is developing differential diagnostic products for cancer. The company’s early disease focus is in leukaemia, prostate and colon cancer.